|
AR071891A1
(es)
*
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
|
HUE045270T2
(hu)
|
2010-01-05 |
2019-12-30 |
Inst Nat Sante Rech Med |
FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
|
|
WO2011113041A2
(en)
*
|
2010-03-12 |
2011-09-15 |
The Johns Hopkins University |
Neutralization of flt3 ligand as a leukemia therapy
|
|
ES2806146T3
(es)
*
|
2011-09-22 |
2021-02-16 |
Amgen Inc |
Proteínas de unión al antígeno CD27L
|
|
JP5798199B2
(ja)
*
|
2012-03-08 |
2015-10-21 |
国立研究開発法人科学技術振興機構 |
抗がん剤
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016145099A1
(en)
|
2015-03-09 |
2016-09-15 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
KR20180053744A
(ko)
*
|
2015-09-23 |
2018-05-23 |
사이토이뮨 테라퓨틱스 엘엘씨 |
면역 요법을 위한 flt3 유도된 car 세포
|
|
ES2987957T3
(es)
|
2015-11-23 |
2024-11-18 |
Novartis Ag |
Vectores de transferencia lentivirales optimizados y usos de los mismos
|
|
BR112018013074A2
(en)
|
2015-12-30 |
2018-12-11 |
Novartis Ag |
immune effector cell therapies with enhanced efficacy
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CA3025516A1
(en)
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
|
MX2018015684A
(es)
|
2016-06-17 |
2019-08-29 |
Magenta Therapeutics Inc |
Composiciones y metodos para el agotamiento de celulas cd117.
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
AU2017382883B2
(en)
|
2016-12-21 |
2024-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
IL268058B2
(en)
|
2017-01-20 |
2023-09-01 |
Magenta Therapeutics Inc |
Compositions and methods for depleting cd137 plus cells
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
JP2020519665A
(ja)
|
2017-05-17 |
2020-07-02 |
アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） |
オピオイドによる痛みの処置を改善する為のｆｌｔ３阻害剤
|
|
PE20241587A1
(es)
*
|
2017-06-02 |
2024-08-01 |
Pfizer |
Receptores de antigenos quimericos que se dirigen a flt3
|
|
PE20242042A1
(es)
*
|
2017-06-02 |
2024-10-10 |
Pfizer |
Anticuerpos especificos para flt3 y sus usos
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EA202090387A1
(ru)
*
|
2017-07-31 |
2020-05-21 |
Драгонфлай Терапьютикс, Инк. |
Белки, связывающие nkg2d, cd16 и flt3
|
|
WO2019084288A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113544152B
(zh)
*
|
2018-12-18 |
2024-10-15 |
勃林格殷格翰国际加拿大公司 |
Flt3激动剂抗体及其用途
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3136618A1
(en)
*
|
2019-04-10 |
2020-10-15 |
Elevatebio Technologies, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
WO2020223445A1
(en)
*
|
2019-04-30 |
2020-11-05 |
Senti Biosciences, Inc. |
Chimeric receptors and methods of use thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
JP2022532837A
(ja)
*
|
2019-05-24 |
2022-07-20 |
エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド |
抗ｃｓｆ１ｒ抗体、ｉｌ１０融合タンパク質、及びそれらの使用
|
|
AR120222A1
(es)
*
|
2019-10-15 |
2022-02-02 |
Dragonfly Therapeutics Inc |
Anticuerpos dirigidos a flt3 y uso de los mismos
|
|
AU2020368163A1
(en)
*
|
2019-10-15 |
2022-04-28 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and FLT3
|
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
|
CA3170833A1
(en)
*
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
JP7525109B2
(ja)
*
|
2020-03-18 |
2024-07-30 |
学校法人金沢医科大学 |
Ｃｄ１３５＋細胞を含む医薬組成物
|
|
PH12022552710A1
(en)
|
2020-04-14 |
2024-03-25 |
Servier Lab |
Anti-flt3 antibodies and compositions
|
|
JP2023522330A
(ja)
|
2020-04-17 |
2023-05-30 |
シティ・オブ・ホープ |
Ｆｌｔ３陽性悪性腫瘍を処置するためのｆｌｔ３標的化キメラ抗原受容体改変細胞
|
|
EP4142749A1
(en)
|
2020-04-30 |
2023-03-08 |
The Regents of the University of Colorado, A Body Corporate |
Multispecific anti-flt3 chimeric antigen receptors
|
|
CN115836088A
(zh)
|
2020-05-06 |
2023-03-21 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和clec12a的蛋白质
|
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
CN111808821B
(zh)
*
|
2020-06-24 |
2022-06-14 |
南方医科大学珠江医院 |
Flt3-nkg2d双靶点car-t的构建与制备
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
MX2023005609A
(es)
|
2020-11-13 |
2023-05-29 |
Novartis Ag |
Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202309294A
(zh)
|
2021-04-27 |
2023-03-01 |
瑞士商諾華公司 |
病毒載體生產系統
|
|
CA3229526A1
(en)
*
|
2021-08-16 |
2023-02-23 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
|
EP4392455A4
(en)
|
2021-08-25 |
2025-08-20 |
Ibio Inc |
ANTI-CD-25 ANTIBODIES
|
|
US20250049939A1
(en)
*
|
2021-12-10 |
2025-02-13 |
Tubulis Gmbh |
Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
EP4720059A1
(en)
|
2023-05-24 |
2026-04-08 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2026052513A1
(en)
*
|
2024-09-09 |
2026-03-12 |
Adcytherix Sas |
Antibody-drug conjugates comprising an flt3 binding antibody
|